ALK抑制剂在治疗NSCLC脑转移中的疗效及安全性研究进展

Lung cancer is one of the most lethal malignancies in the world, with non-small cell lung cancer (NSCLC) accounting for approximately 80%-85% of all pathological types. Approximately 30%-55% of NSCLC patients develop brain metastases. It has been reported that 5%-6% of patients with brain metastases...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuchen, CHEN, Han, HAN, Jinpan, WEI, Qianyu, DU, Xiyong, WANG
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial board of Chinese Journal of Lung Cancer 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10273149/
https://www.ncbi.nlm.nih.gov/pubmed/37316450
http://dx.doi.org/10.3779/j.issn.1009-3419.2023.101.10

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10273149/
https://www.ncbi.nlm.nih.gov/pubmed/37316450
http://dx.doi.org/10.3779/j.issn.1009-3419.2023.101.10

Ejemplares similares